Search Results - "Krischer, J.P"

A cross-sectional multicenter study of osteogenesis imperfecta in North America - results from the linked clinical research centers by Patel, R.M., Nagamani, S.C.S., Cuthbertson, D., Campeau, P.M., Krischer, J.P., Shapiro, J.R., Steiner, R.D., Smith, P.A., Bober, M.B., Byers, P.H., Pepin, M., Durigova, M., Glorieux, F.H., Rauch, F., Lee, B.H., Hart, T., Sutton, V.R.

“…Osteogenesis imperfecta (OI) is the most common skeletal dysplasia that predisposes to recurrent fractures and bone deformities. In spite of significant…”
Get full text

An automated communication system in a contact registry for persons with rare diseases: Scalable tools for identifying and recruiting clinical research participants by Richesson, R.L, Lee, H.S, Cuthbertson, D, Lloyd, J, Young, K, Krischer, J.P

“…Abstract Objectives Strategies for study recruitment are useful in clinical research network settings. We describe a registry of individuals who have…”
Get full text

Clinical severity and quality of life in children and adolescents with Rett syndrome by LANE, J. B, LEE, H.-S, ANNESE, F, MCNAIR, L, GRAHAM, J, KHWAJA, O, BARNES, K, KRISCHER, J. P, SMITH, L. W, CHENG, P, PERCY, A. K, GLAZE, D. G, NEUL, J. L, MOTIL, K. J, BARRISH, J. O, SKINNER, S. A

“…The clinical features and genetics of Rett syndrome (RTT) have been well studied, but examination of quality of life (QOL) is limited. This study describes the…”
Get full text

Prevalence of obesity was related to HLA-DQ in 2–4-year-old children at genetic risk for type 1 diabetes by Yang, J, Lernmark, Å, Uusitalo, U M, Lynch, K F, Veijola, R, Winkler, C, Larsson, H E, Rewers, M, She, J-X, Ziegler, A G, Simell, O G, Hagopian, W A, Akolkar, B, Krischer, J P, Vehik, K

“…Objectives: Body size is postulated to modulate type 1 diabetes as either a trigger of islet autoimmunity or an accelerator to clinical onset after…”
Get full text

phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer by Kumar, N.B, Krischer, J.P, Allen, K, Riccardi, D, Besterman-Dahan, K, Salup, R, Kang, L, Xu, P, Pow-Sang, J

“…Our purpose was to evaluate the safety and effectiveness of purified isoflavones in producing an increase in plasma isoflavones and a corresponding change in…”
Get full text

Country-specific birth weight and length in type 1 diabetes high-risk HLA genotypes in combination with prenatal characteristics by Sterner, Y, Törn, C, Lee, H-S, Larsson, H, Winkler, C, McLeod, W, Lynch, K, Simell, O, Ziegler, A, Schatz, D, Hagopian, W, Rewers, M, She, J-X, Krischer, J P, Akolkar, B, Lernmark, Å

“…Objective: To examine the relationship between high-risk human leukocyte antigen (HLA) genotypes for type 1 diabetes and birth size in combination with…”
Get full text

Safety of purified isoflavones in men with clinically localized prostate cancer by Kumar, N.B, Krischer, J.P, Allen, K, Riccardi, D, Besterman-Dahan, K, Salup, R, Kang, L, Xu, P, Pow-Sang, J

“…Our purpose was to evaluate the safety of 80 mg of purified isoflavones administered to men with early stage prostate cancer. A total of 53 men with clinically…”
Get full text

Acute Myeloid Leukemia (AML) in Down’s Syndrome Is Highly Responsive to Chemotherapy: Experience on Pediatric Oncology Group AML Study 8498 by Ravindranath, Y., Abella, E., Krischer, J.P., Wiley, J., Inoue, S., Harris, M., Chauvenet, A., Alvarado, C.S., Dubowy, R., Ritchey, A.K., Land, V., Steuber, C.P., Weinstein, H.

“…The treatment of acute myeloid leukemia (AML) in children with Down’s syndrome (DS) has engendered considerable controversy. Because of the concerns for…”
Get full text

Knowledge acquisition for clinical-trial selection by Nikiforou, S., Fink, E., Hall, L.O., Goldgof, D.B., Krischer, J.P.

Get full text

A cost-effective agent for clinical trial assignment by Kokku, P.K., Hall, L.O., GoIdgof, D.B., Fink, E., Krischer, J.P.

Get full text

Age and family relationship accentuate the risk of insulin-dependent diabetes mellitus (IDDM) in relatives of patients with IDDM by Cantor, A B, Krischer, J P, Cuthbertson, D D, Schatz, D A, Riley, W J, Malone, J, Schwartz, S, Quattrin, T, Maclaren, N K

“…The international community of diabetologists is rapidly becoming involved in intervention trials aimed at preventing insulin-dependent diabetes in high risk…”
Get more information

Experiments on the automated selection of patients for clinical trials by Fink, E., Hall, L.O., Goldgof, D.B., Goswami, B.D., Boonstra, M., Krischer, J.P.

“…When clinicians test a new treatment procedure, they need to identify and recruit patients with appropriate medical conditions. We have developed an expert…”
Get full text

Using probabilistic methods to optimize data entry in accrual of patients to clinical trials by Goswami, B.D., Hall, L.O., Goldgof, D.B., Fink, E., Krischer, J.P.

“…A clinical trial is a study conducted on a group of patients to evaluate a new treatment procedure. Usually, clinicians manually select patients for a clinical…”
Get full text

An expert system for evaluating risk in type-1 diabetes by Nallamshetty, L., Eschrich, S.A., Cuthbertson, D., Malloy, J., Goldgof, D.B., Alexander, A.M., Trucco, M., Ilonen, J., Akerblom, H.K., Krischer, J.P.

“…Type-1 diabetes is a life-long disorder that often occurs in children or young adults. Susceptibility to type-1 diabetes is believed to be dependent on both…”
Get full text

Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience by Krischer, J.P, Cuthbertson, D.D, Epstein, S, Goorin, A.M, Epstein, M.L, Lipshultz, S.E

“…Purpose: To evaluate risk factors for clinical cardiotoxicity from anthracycline chemotherapy in children with cancer and to estimate the relative risk…”
Get full text